Epidemiology of infections caused by multiresistant Gram-negatives: ESBLs, MBLs, panresistant strains

New Microbiologica

Volumn 30, Issue 3, 2007, Pages 332-339

  Rossolini, Gian Maria ^a,b   Mantengoli, Elisabetta ^a   Docquier, Jean Denis ^a   Musmanno, Rosa Anna ^a   Coratza, Grazietta ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Acinetobacter; Carbapenemases; Enterobacteriaceae; Epidemiology; Extended spectrum lactamases; Multidrug resistance; Panresistance; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; DRUG EFFECT; ENZYMOLOGY; EUROPE; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; NORTH AMERICA;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA;

ACINETOBACTER; ENTEROBACTERIACEAE; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 34547939642     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ALVAREZ, M., TRAN, J.H., CHOW, N., JACOBY, G.A. (2004). Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob Agents Chemother. 48 (2), 533-537.
2. BERGOGNE-BEREZIN, E., TOWNER, K.J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 9 (2), 148-165.
3. BONOMO, R.A., SZABO, D. (2006). Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 43 (Suppl 2), 49-56.
4. BRADFORD, P.A. (2001). Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 14 (4), 933-951.
5. CORBELLA, X., MONTERO, A., PUJOL, M., DOMINGUEZ, M.A., AYATS, J., ARGERICH, M.J., GARRIGOSA, F., ARIZA, J., GUDIOL, F. (2000). Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol. 38 (11), 4086-4095.
6. COSGROVE, S.E. (2006). The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 42 (Suppl. 2), 82-89.
7. DESHPANDE, L.M., RHOMBERG, P.R., SADER, H.S., JONES, R.N. (2006). Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis. 56 (4), 367-372.
8. ENDIMIANI, A., LUZZARO, F., PERILLI, M., LOMBARDI, G., COLI, A., TAMBURINI, A., AMICOSANTE, G., TONIOLO, A. (2004). Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 38 (2), 243-251.
9. EUROPEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE SYSTEM. (2006). EARSS Annual Report 2005. Bilthoven: RIVM. Available at: http://www.earss.rivm.nl.
10. GALANI, I., SOULI, M., KORATZANIS, E., KORATZANIS, G., CHRYSSOULI, Z., GIAMARELLOU, H. (2007). Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-β-lactamase VIM-1 in Greece. J Antimicrob Chemother. 25.
11. GALES, A.C., JONES, R.N., SADER, H.S. (2006). Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 12 (4), 315-321.
12. GIAKKOUPI, P., XANTHAKI, A., KANELOPOULOU, M., VLAHAKI, A., MIRIAGOU, V., KONTOU, S., PAPAFRAGGAS, E., MALAMOU-LADA, H., TZOUVELEKIS, L.S., LEGAKIS, N.J., VATOPOULOS, A.C. (2003). VIM-1 Metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol. 41 (8): 3893-3896.
13. HOOPER, D.C. (2003). Mechanisms of Quinolone Resistance. In: Hooper, D.C., Rubinstein, E., eds. Quinolone antimicrobial agents. 3th edn. Washington, DC: ASM Press, p. 41-67.
14. IKONOMIDIS, A., TOKATLIDOU, D., TRISTO, I., SOFIANOU, D., TSAKRIS, A., MANTZANA, P., POURNARAS, S., MANIATIS, A.N. (2005). Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-β-lactamase gene. J Clin Microbiol. 43 (10): 5344-5347.
15. JONES, M.E., DRAGHI, D.C., THORNSBERRY, C., KARLOWSKY, J.A., SAHM, D.F., WENZEL, R.P. (2004). Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 3: 14-24.
16. LEPPER, P.M., GRUSA, E., REICHL, H., HOGEL, J., TRAUTMANN, M. (2002). Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 46 (9), 2920-2925.
17. LIVERMORE, D.M. (1995). β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 8 (4), 557-584.
18. LIVERMORE, D.M. (2001). Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 47 (3), 247-250.
19. LIVERMORE, D.M. (2002). Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 34 (5), 634-640.
20. LIVERMORE, D.M., CANTON, R., GNIADKOWSKI, M., NORDMANN, P., ROSSOLINI, G.M., ARLET, G., AYALA, J., COQUE, T.M., KERN-ZDANOWICZ, I., LUZZARO, F., POIREL, L., WOODFORD, N. (2007). CTX-M: chang ing the face of ESBLs in Europe. J Antimicrob Chemother. 59 (2), 165-174.
21. MIRIAGOU, V., TZELEPI, E., DAIKOS, G.L., TASSIOS, P.T., TZOUVELEKIS, L.S. (2005). Panresistance in VIM-1-producing Klebsiella pneumoniae. J Antimicrob Chemother. 55 (5), 810-811.
22. OBRITSCH, M.D., FISH, D.N., MACLAREN, R., JUNG, R. (2004). National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 48 (12), 4606-4610.
23. PARK, C.H., ROBICSEK, A., JACOBY, G.A., SAHM, D., HOOPER, D.C. (2006). Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother. 50 (11), 3953-3955.
24. PATERSON, D.L., BONOMO, R.A. (2005). Extended-spectrum β-lactamases: a clinicai update. Clin Microbiol Rev. 18 (4), 657-686.
25. PIER, G.B., RAMPHAL, R. (2005). Pseudomonas aeruginosa. In: Mandell, G.L., Bennett, J.E., Dolin, R., eds. Principles and Practice of Infectious Diseases. 6th edn. Philadelphia, PA: Churchill Livingstone, 2587-2614.
26. POIREL, L., MENUTEAU, O., AGOLI, N., CATTOEN, C., NORDMANN, P. (2003). Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol. 41 (8), 3542-3547.
27. POIREL, L., NORDMANN, P. (2006). Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 12 (9), 826-836.
28. ROBICSEK, A., JACOBY, G.A., HOOPER, D.C. (2006). The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 6(10), 629-640.
29. RONALD, A. (2002). The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 113 (Suppl. 1A), 14-19.
30. ROSSOLINI, G.M. (2005). Acquired metallo-β-lactamases: an increasing clinical threat. Clin Infect Dis. 41 (11), 1557-1558.
31. ROSSOLINI, G.M., DOCQUIER, J.D. (2006). New β-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting. Fut Microbiol. 1 (3), 295-308.
32. ROSSOLINI, G.M., MANTENGOLI, E. (2005). Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 11 (Suppl 4), 17-32.
33. SCHWABER, M.J., CARMELI, Y. (2006). Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care. 10 (5), 164.
34. STYERS, D., SHEEHAN, D.J., HOGAN, P., SAHM, D.F. (2006). Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 5, 2.
35. URBAN, C., SEGAL-MAURER, S., RAHAL, J.J. (2003). Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis. 36 (10), 1268-1274.
36. VAN LOOVEREN, M., GOOSSENS, H.; ARPAC Steering Group. (2004). Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 10 (8), 684-704.
37. WALSH, T.R., TOLEMAN, M.A., POIREL, L., NORDMANN, P. (2005). Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev. 18 (2), 306-325.
38. YAN, J.J., HSUEH, P.R., LU, J.J., CHANG, F.Y., SHYR, J.M., WAN, J.H., LIU, Y.C., CHUANG, Y.C., YANG, Y.C., TSAO, S.M., WU, H.H., WANG, L.S., LIN, T.P., WU, H.M., CHEN, H.M., WU, J.J. (2006). Extended-spectrum β-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan. Antimicrob Agents Chemother. 50 (5): 1861-1864.